Carcinosarcomas (Malignant Mixed Mullerian Tumor) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Carcinosarcomas, also known as malignant mixed Müllerian tumors (MMMT), are uncommon malignancies that demonstrate both epithelial (carcinomatous) and mesenchymal (sarcomatous) differentiation. While most carcinosarcomas arise in the uterus, they can also develop in the ovaries, fallopian tubes, cervix, and, very rarely, the female peritoneum. These tumors predominantly affect older postmenopausal individuals, with 90% of cases occurring in those over 50 years of age. MMMTs are classified as high-grade endometrial carcinomas and are characterized by both a carcinomatous and a sarcomatous component. Risk factors for MMMT include nulliparity, obesity, advanced age, exposure to exogenous estrogens, pelvic irradiation, and long-term use of tamoxifen. MMMTs are highly aggressive tumors with a poor prognosis, comprising only 1–2% of uterine neoplasms and responsible for 15% of deaths from uterine malignancy. MMMT is characterized by a carcinomatous and a sarcomatous component, and the sarcoma can contain either homologous or heterologous, nonnative elements. Prognostic factors for MMMT include surgical stage, lymphovascular space invasion (LVSI), depth of myometrial invasion, tumor histology, and patient age.
·
The five-year survival rate for patients with
MMMT ranges between 33% and 39%.
·
In the United States, the annual incidence of
uterine sarcomas is about 2 per 100,000 women; more than 50% are MMMTs.
Thelansis’s “Carcinosarcomas
(Malignant Mixed Mullerian Tumor) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Carcinosarcomas
(Malignant Mixed Mullerian Tumor) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Carcinosarcomas (Malignant Mixed Mullerian Tumor) across 8 MM market from
the centre of Excellence/ Public/ Private hospitals participated in the study.
Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm, and Unmet needs.
Carcinosarcomas (Malignant Mixed
Mullerian Tumor) Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment